These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27672311)

  • 21. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.
    Katsetos CD; Dráberová E; Legido A; Dumontet C; Dráber P
    J Cell Physiol; 2009 Dec; 221(3):505-13. PubMed ID: 19650075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The neural adhesion molecule L1CAM confers chemoresistance in human glioblastomas.
    Held-Feindt J; Schmelz S; Hattermann K; Mentlein R; Mehdorn HM; Sebens S
    Neurochem Int; 2012 Dec; 61(7):1183-91. PubMed ID: 22948185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme.
    Vogel TW; Zhuang Z; Li J; Okamoto H; Furuta M; Lee YS; Zeng W; Oldfield EH; Vortmeyer AO; Weil RJ
    Clin Cancer Res; 2005 May; 11(10):3624-32. PubMed ID: 15897557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells.
    Farace C; Oliver JA; Melguizo C; Alvarez P; Bandiera P; Rama AR; Malaguarnera G; Ortiz R; Madeddu R; Prados J
    PLoS One; 2015; 10(7):e0134111. PubMed ID: 26230845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
    Tabuchi S
    Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designer therapies for glioblastoma multiforme.
    Sathornsumetee S; Rich JN
    Ann N Y Acad Sci; 2008 Oct; 1142():108-32. PubMed ID: 18990124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells.
    Galavotti S; Bartesaghi S; Faccenda D; Shaked-Rabi M; Sanzone S; McEvoy A; Dinsdale D; Condorelli F; Brandner S; Campanella M; Grose R; Jones C; Salomoni P
    Oncogene; 2013 Feb; 32(6):699-712. PubMed ID: 22525272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
    Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies.
    Denysenko T; Gennero L; Roos MA; Melcarne A; Juenemann C; Faccani G; Morra I; Cavallo G; Reguzzi S; Pescarmona G; Ponzetto A
    Cell Biochem Funct; 2010 Jul; 28(5):343-51. PubMed ID: 20535838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitizer drugs for the treatment of temozolomide-resistant glioblastoma.
    Baritchii A; Jurj A; Soritau O; Tomuleasa C; Raduly L; Zanoaga O; Cernea D; Braicu C; Neagoe I; Stefan Florian I
    J BUON; 2016; 21(1):199-207. PubMed ID: 27061549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of tumor formation and redirected differentiation of glioblastoma cells in a xenotypic embryonic environment.
    Joel M; Sandberg CJ; Boulland JL; Vik-Mo EO; Langmoen IA; Glover JC
    Dev Dyn; 2013 Sep; 242(9):1078-93. PubMed ID: 23780720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MLK3 Is Associated With Poor Prognosis in Patients With Glioblastomas and Actin Cytoskeleton Remodeling in Glioblastoma Cells.
    Zhu Y; Sun JM; Sun ZC; Chen FJ; Wu YP; Hou XY
    Front Oncol; 2020; 10():600762. PubMed ID: 33692940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glioblastoma-specific anti-TUFM nanobody for
    Samec N; Jovcevska I; Stojan J; Zottel A; Liovic M; Myers MP; Muyldermans S; Šribar J; Križaj I; Komel R
    Oncotarget; 2018 Apr; 9(25):17282-17299. PubMed ID: 29707108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of CD133 positive stem cell proportion on survival in patients with glioblastoma multiforme.
    Kase M; Minajeva A; Niinepuu K; Kase S; Vardja M; Asser T; Jaal J
    Radiol Oncol; 2013; 47(4):405-10. PubMed ID: 24294187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs.
    Whitehead CA; Nguyen HPT; Morokoff AP; Luwor RB; Paradiso L; Kaye AH; Mantamadiotis T; Stylli SS
    Transl Oncol; 2018 Dec; 11(6):1406-1418. PubMed ID: 30219696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SuperQuant-assisted comparative proteome analysis of glioblastoma subpopulations allows for identification of potential novel therapeutic targets and cell markers.
    Verano-Braga T; Gorshkov V; Munthe S; Sørensen MD; Kristensen BW; Kjeldsen F
    Oncotarget; 2018 Feb; 9(10):9400-9414. PubMed ID: 29507698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR96- and miR182-driven regulation of cytoskeleton results in inhibition of glioblastoma motility.
    Akdaş EY; Temizci B; Karabay A
    Cytoskeleton (Hoboken); 2023; 80(9-10):367-381. PubMed ID: 36961307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of glioblastoma by a drug cocktail reprogramming tumor cells into neuronal like cells.
    Gao L; Huang S; Zhang H; Hua W; Xin S; Cheng L; Guan W; Yu Y; Mao Y; Pei G
    Sci Rep; 2019 Mar; 9(1):3462. PubMed ID: 30837577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.